Total current assets Total assets Related and Nonrelated Parties [Axis] Total current liabilities Total liabilities Class of Stock [Axis] Total stockholders’ equity Balances Balances Total liabilities, convertible preferred stock and stockholders’ equity Statement of Income Location, Balance [Axis] Total operating expenses Loss from operations Loss from operations Total other income, net Net loss Net loss Net loss (in Dollars) Comprehensive loss Balances (in Shares) Balances (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash operating activities (in Dollars) Net cash used in investing activities Net cash provided by financing activities Net increase in cash and cash equivalents Cash at beginning of period Cash and cash equivalents at end of period Nature of the Business and Basis of Presentation [Abstract] Summary of Significant Accounting Policies [Abstract] Long-Lived Tangible Asset [Axis] Statistical Measurement [Axis] Reverse Recapitalization and Pre-Closing Financing [Abstract] Schedule of the Assets and Liabilities [Abstract] Net assets acquired Fair Value Measurements [Abstract] Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Cash equivalents and Marketable Securities [Abstract] Financial Instrument [Axis] Cash and Cash Equivalents [Axis] Marketable Securities [Axis] Schedule of Marketable Securities at Estimated Fair Value [Abstract] Total Accrued Expenses and Other Current Liabilities [Abstract] Schedule of Accrued Expenses and Other Current Liabilities [Abstract] Total Accrued expenses and other current liabilities Note Payable with Related Party [Abstract] Convertible Preferred Stock and Stockholders’ Equity [Abstract] Class of Warrant or Right [Axis] Plan Name [Axis] Stock-Based Compensation [Abstract] Number of Stock Options Outstanding, Ending Balance Weighted Average Exercise Price Per Share, Ending Balance Aggregate Intrinsic Value, Ending Balance Beginning Balance (in Shares) Ending Balance (in Shares) Weighted Average Grant Date Fair Value, Unvested balance, Beginning Weighted Average Grant Date Fair Value, Unvested balance, Ending Weighted Average Grant Date Fair Value, Granted Beginning Balance (in Shares) Ending Balance (in Shares) Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Segment Disclosures [Abstract] Income Taxes [Abstract] Schedule of Loss Before Income Tax Expense [Abstract] Loss before income tax expense Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract] Income tax (benefit) expense Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract] Total deferred tax assets Total deferred tax liabilities Deferred tax assets, net Schedule of Net Deferred Tax Assets [Abstract] Deferred tax assets Beginning balance Ending balance Less valuation allowance Schedule of Unrecognized Tax Benefits [Abstract] Beginning balance Ending balance Option Agreements and License Agreements [Abstract] Commitment and Contingencies [Abstract] Schedule of Company’s Supplemental Cash Flow Information Related to Leases [Abstract] Supplemental disclosures of non-cash operating and financing activities: Schedule of Company’s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract] Total undiscounted lease payments Future lease payment Total discounted lease payments Net Loss per Share [Abstract] Antidilutive Securities [Axis] Related Party Transactions [Abstract] Subsequent Events [Abstract] Assets Current assets: Cash and cash equivalents Marketable securities, current Due in one year or less Subscription receivable Prepaid expenses and other current assets Marketable securities, long-term Due in 1-2 years Property and equipment, net Operating lease right-of-use assets Other non-current assets Liabilities, Convertible Preferred Stock and Stockholders’ Equity Current liabilities: Accounts payable Operating lease liability, current Less: current portion of lease liability Related party accounts payable and other current liabilities Accounts payable and other current liabilities Operating lease liability, non-current Non-current portion of lease liability Operating lease liability, noncurrent Commitments and contingencies (Note 13) Convertible preferred stock, value Convertible preferred stock, par value (in Dollars per share) Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Stockholders’ equity: Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively Carrying Value (in Dollars) Non-voting convertible preferred stock, par value (in Dollars per share) Non-voting convertible preferred stock, shares authorized Preferred Stock Authorized Non-voting convertible preferred stock, shares issued Preferred Stock Issued Non-voting convertible preferred stock, shares outstanding Preferred Stock Outstanding Preferred stock, shares outstanding Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Operating expenses Research and development Research and development personnel-related expense (excluding stock-based compensation) Related party amount General and administrative General and administrative personnel-related expense (excluding stock-based compensation) Other income (expense) Interest income Other income, net Unrealized loss on marketable securities Net loss per share attributable to stockholders, basic (in Dollars per share) Loss per share – Basic Net loss per share attributable to stockholders, diluted (in Dollars per share) Loss per share – Diluted Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) Weighted average shares outstanding – Basic Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) Weighted average shares outstanding – Diluted Issuance of common stock Issuance of common stock (in Shares) Issuance of Series A convertible preferred stock, net of issuance costs of $69 Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares) Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares) Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares) Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares) Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares) Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares) Issuance costs of PIPE Financing Conversion of Series A non-voting convertible preferred stock to common stock Conversion of Series A non-voting convertible preferred stock to common stock (in Shares) Issuance of common stock under employee stock purchase plan Issuance of common stock under employee stock purchase plan (in Shares) Reclassification of the Paruka warrant from liability to equity Stock-based compensation expense Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense Non-cash interest expense Non-cash lease expense Depreciation expense Changes in operating assets and liabilities: Accounts payable Accrued expenses and other current liabilities Operating lease liability Related party accounts payable and other current liabilities Cash flows from investing activities: Cash flows from financing activities: Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid Gross proceeds (in Dollars) Proceeds from issuance of notes payable to related party, net of issuance costs paid Proceeds from the Pre-Closing Financing, net Proceeds from the PIPE Financing, net Cash acquired in connection with the reverse recapitalization Proceeds from issuance of common stock Operating lease liability arising from obtaining operating right-of-use asset Assets acquired in connection with the reverse capitalization Non-cash accrued interest on convertible note converted to common stock Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock Conversion of Series A non-voting convertible preferred stock to common stock Reclassification of the Paruka warrant from liability to equity Interest expense Issuance costs of Pre-Closing Financing and reverse recapitalization Net accretion of premiums and discounts on marketable securities Prepaid expenses and other current assets Other non-current assets Purchases of property and equipment Purchases of marketable securities